Last reviewed · How we verify
NCT06649123: TRIOMIC
Triple Assay of Rectal Mucus in the Diagnosis of Colorectal Cancer
trial testing Oricol Test in Colorectal Cancer in 6,600 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Origin Sciences |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 6,600 |
| Start date | 1 November 2024 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2027 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Oricol Test
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Adenoma Colon Polyp — all drugs for Adenoma Colon Polyp →
Sponsor
Origin Sciences — full company profile →
Who can join
Adults 18 to 99, any sex, with Colorectal Cancer or Adenoma Colon Polyp. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Development of a multiomics assay for use on OriColTM sampled rectal mucus for detection of cancer and significant polyps in symptomatic patients on the Colorectal Urgent Suspected Cancer pathway.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Late-breaking trials in IBD.
· 2025 · PMID 41178467 · DOI 10.1002/ueg2.70130
Verify or expand the search:
- PubMed search for NCT06649123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oricol Test
Trials testing the same drug.
- NCT05102110 — Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer. · recruiting
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Origin Sciences trials
Trials by the same sponsor.
- NCT05709119 — Feasibility of the Oricol™ Sampling Device to Retrieve Vagina Mucus (Wall) Samples for Genomic & Epigenetic Analysis. · completed
- NCT05102110 — Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer. · recruiting
- NCT04659590 — Exploratory Study of Rectal Mucus for Diagnosing Disease · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06649123 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Origin Sciences
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06649123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing